Cargando...
Five‐year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
We report the 5‐year follow‐up results from a single‐arm, open‐label, multicenter phase II study (ONO‐4538‐08) conducted in Japan. Twenty‐four patients with treatment‐naïve, recurrent, or unresectable stage III/IV malignant melanoma received 3 mg/kg nivolumab every 2 weeks until progressive disease...
Guardado en:
| Publicado en: | J Dermatol |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8252056/ https://ncbi.nlm.nih.gov/pubmed/33715172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1346-8138.15804 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|